Geneva: The periodic update of viruses contained in influenza vaccines is necessary for the vaccines to be effective due to the constant evolving nature of influenza viruses, including those circulating and infecting humans. Twice annually, the World Health Organisation (WHO) organises consultations with an advisory group of experts to analyse influenza virus surveillance data generated by the WHO Global Influenza Surveillance and Response System (GISRS), and issues recommendations on the composition of the influenza vaccines for the following influenza season. These recommendations are used by the national vaccine regulatory agencies and the pharmaceutical companies to develop, produce and license influenza vaccines.
The WHO recommendation on the composition of influenza virus vaccines for use in the northern hemisphere 2021-2022 was announced in the WHO Information Meeting and Round-table Discussion with manufacturers and regulatory agencies today, February 26, 2021.
It followed the 7-day virtual Consultation Meeting with Advisers from WHO Collaboration Centres (CCs) and WHO Essential Regulatory Laboratories (ERLs) based on year-round surveillance by the WHO Global Influenza Surveillance and Response System (GISRS).
It is recommended thatquadrivalent vaccines for use in the 2021-2022 northern hemisphere influenza season contain the following:
Egg-based Vaccines
- an A/Victoria/2570/2019 (H1N1)pdm09-like virus;
- an A/Cambodia/e0826360/2020 (H3N2)-like virus;
- a B/Washington/02/2019 (B/Victoria lineage)-like virus; and
- a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
Cell- or recombinant-based Vaccines
- an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
- an A/Cambodia/e0826360/2020 (H3N2)-like virus;
- a B/Washington/02/2019 (B/Victoria lineage)-like virus; and
- a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
It is recommended that trivalent influenza vaccines for use in the 2021-2022 northern hemisphere influenza season contain the following:
Egg-based Vaccines
- an A/Victoria/2570/2019 (H1N1)pdm09-like virus;
- an A/Cambodia/e0826360/2020 (H3N2)-like virus; and
- a B/Washington/02/2019 (B/Victoria lineage)-like virus.
Cell- or recombinant-based Vaccines
- an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
- an A/Cambodia/e0826360/2020 (H3N2)-like virus; and
- a B/Washington/02/2019 (B/Victoria lineage)-like virus.
– global bihari bureau
Do you mind if I quote a couple of your posts as long as I provide credit and sources back to your weblog? My blog is in the very same area of interest as yours and my visitors would genuinely benefit from a lot of the information you present here. Please let me know if this okay with you. Thanks!